Inex/Enzon's Marqibo Accelerated Approval Application "Not Approvable"

FDA recommends additional randomized studies comparing Marqibo to other chemotherapy agents; the agency also cites CMC deficiencies. The "not approvable" letter follows a negative committee review for the non-Hodgkin's lymphoma therapy.